<DOC>
	<DOCNO>NCT02243176</DOCNO>
	<brief_summary>SMART Study - A 24-Week , Multicenter , Randomized , Parallel-group , Open-label , Active Controlled Phase IV Study Assess Efficacy , Safety Tolerability Saxagliptin Compared Acarbose Combination Metformin Patients Type 2 Diabetes Mellitus ( T2D ) Inadequately Controlled Metformin Monotherapy</brief_summary>
	<brief_title>24-Week , Multicenter , Randomized , Parallel-group , Open-label , Active Controlled Phase IV Study Assess Efficacy , Safety Tolerability Saxagliptin Compared With Acarbose When Combination With Metformin Patients With T2D Inadequately Controlled With Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>1 . Diagnosed type 2 diabetes mellitus 2 . Men woman ( nonpregnant use medically approve birthcontrol method ) age least 18 year screen . 3 . T2D patient treat stable metformin monotherapy least 8 week prior screen . Metformin dose ≥ 1500 mg/day ( individual maximally tolerate dose ) , maximum dose specify label 4 . HbA1c ≥ 7.5 % ≤ 11.0 % screen within 4 week prior screen ( local laboratory ) HbA1c ≥ 7.0 % ≤ 11.0 % prerandomization visit ( central laboratory ) 5 . FPG ≤ 13.3 mmol/L ( ≤ 240 mg/dL ) prerandomization visit ( central laboratory ) 6 . Able willing provide write informed consent comply study protocol 1 . Women pregnant , intend become pregnant study period , lactate female , woman childbearing potential use highly effective , medically approve birth control method . 2 . Diagnosis history : 1 . Type 1 diabetes mellitus , diabetes result pancreatic injury secondary form diabetes , eg , acromegaly Cushing 's syndrome . 2 . Acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month . 3 . Previous treatment dipeptidyl peptidase4 ( DPP4 ) inhibitor GLP1 receptor agonist within past one year . 4 . History hypersensitivity reaction ( e.g. , anaphylaxis , angioedema , exfoliative skin condition ) dipeptidyl peptidase4 inhibitor ( DPP4 ) Acarbose . 5 . Treatment antidiabetic medication 7 consecutive day metformin last 8 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Saxagliptin</keyword>
	<keyword>Acarbose</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Metformin</keyword>
</DOC>